A Phase I/II Study of Bevacizumab, Erlotinib and 5-Fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer

Trial Profile

A Phase I/II Study of Bevacizumab, Erlotinib and 5-Fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Fluorouracil (Primary)
  • Indications Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jul 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 19 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jun 2010 Planned end date changed from 1 May 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top